Intelligent Bio Solutions Inc. Announces Progress Toward Completion of Clinical Study Plan Required for FDA 510(k) Submission NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...

Intelligent Bio Solutions Partners with CenExel to Conduct Clinical Study as Part of FDA 510(k) Pathway Intelligent Bio Solutions Inc. (INBS) partners with CenExel to perform a method comparison clinical study as part of the Company’s FDA clinical study plan.

Intelligent Bio Solutions Inc. Advances on FDA 510(k) Pathway with Biocompatibility Study Success NEW YORK, July 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...

NeuroOne® Receives FDA 510(k) Clearance to Market its OneRF™ Ablation System First FDA-cleared thin-film, sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue with the added benefit of temperature control; Marks the Company’s third...

Matrix Surgical USA Receives 510(k) Clearance for OmniPore® DUROMAX® Surgical Implants for Orbital Reconstruction ATLANTA, Ga., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Matrix Surgical USA (www.matrixsurgicalusa.com), a leader in the development, manufacturing and commercialization of craniomaxillofacial implants,...